fda tirzepatide weight loss Is Approved? New weight loss drug could

MDL 3094 In Re: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAS) Products Liability Litigation

were currently enrolled in any other clinical study involving an investigational product or any other type of medical research judged not to be scientifically or medically compatible with this study 37

Treatment discontinuation for any reason occurred in 6.1% of patients receiving tirzepatide and 8.0% of those receiving semaglutide [22]

Factors affecting pricing include compounding pharmacy costs, active pharmaceutical ingredient availability and pricing, regulatory changes, operational expenses, market conditions, and individual patient circumstances